Summary
A prespecified analysis of left ventricular hypertrophy (LVH) as evaluated by electrocardiography from the Olmesartan Medoxomil in Diabetes Mellitus study [ROADMAP] showed that olmesartan significantly reduced LV remodeling in patients with type 2 diabetes mellitus, independent of blood pressure, age, and sex.
- Hypertensive Disease
- Diabetes & Endocrinology Clinical Trials
- Diabetes Mellitus
- Hypertensive Disease
- Diabetes & Endocrinology Clinical Trials
- Endocrinology
- Diabetes & Metabolic Syndrome
- Diabetes Mellitus
- © 2013 MD Conference Express®
Tools
Table of contents
Cited By...
- No citing articles found.